시장보고서
상품코드
1955329

에스트로겐 차단제 시장 보고서(2026년)

Estrogen Blockers Global Market Report 2026

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

에스트로겐 차단제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 100억 5,000만 달러에서 2026년에는 107억 9,000만 달러로, CAGR 7.3%로 확대될 전망입니다. 지난 수년간의 성장에는 에스트로겐 차단제의 공급 제한, 기존 화학요법에 대한 의존도, 유방암 발생률 증가, 호르몬 요법에 대한 인식 부족, 병원 및 종양 클리닉의 인프라 확충 등이 요인으로 작용한 것으로 보입니다.

에스트로겐 차단제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 141억 6,000만 달러에 달하고, CAGR은 7.0%를 기록할 전망입니다. 예측 기간 동안 성장 요인으로는 병용요법 및 천연 유래 에스트로겐 차단제 개발, 맞춤형 의료 접근법 확대, 온라인 약국 채널 채택 증가, 정부 및 의료기관의 유방암 대책 강화, 호르몬 수용체 검사를 위한 첨단 진단 기술 발전 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 선택적 에스트로겐 수용체 조절제(SERM) 및 아로마타제 억제제의 도입 증가, 호르몬 대체요법(HRT)에서 에스트로겐 차단제 사용 확대, 맞춤형 유방암 치료 프로토콜의 성장, 온라인 및 소매 약국 유통 채널 확대, 불임 및 폐경후 골다공증 관리에 대한 인식 증가 등이 있습니다. 불임 및 폐경후 골다공증 관리에 대한 인식 증가 등이 있습니다.

유방암 유병률 증가는 향후 몇 년 동안 에스트로겐 차단제 시장의 성장을 견인할 것으로 예상됩니다. 유방암은 유방 조직에 발생하는 악성 종양으로, 주로 유관 및 소엽에 영향을 미칩니다. 정상 유방 세포가 돌연변이를 일으켜 통제할 수 없는 세포 증식과 종양 형성을 일으켜 발생합니다. 유방암 발생률의 증가는 고령화, 알코올 섭취 증가, 운동 부족 등 생활습관 변화, 검진 및 진단법 향상으로 인한 검진율 증가 등의 요인에 기인합니다. 에스트로겐 차단제는 특정 유방암 세포의 증식을 촉진할 수 있는 호르몬인 에스트로겐의 작용을 억제하여 유방암 치료를 돕습니다. 에스트로겐을 차단함으로써 호르몬 수용체 양성 유방암의 진행을 늦추거나 멈추게 하여 치료를 돕고 재발의 가능성을 낮추는 치료법입니다. 예를 들어, 호주 정부 기관인 호주보건복지연구원(AIHW)에 따르면, 2024년 1월 기준 2023년 여성에서 새로 진단된 유방암 사례는 약 2만 458건이며, 이는 연령 조정된 발병률로 여성 10만 명당 128.6건에 해당합니다. 2022년에는 약 2만 4천 건이 보고되었고, 연령을 조정한 발병률은 여성 10만 명당 128.2건이었습니다. 따라서 유방암의 유병률 증가는 에스트로겐 차단제 시장 확대에 기여하고 있습니다.

에스트로겐 차단제 시장의 주요 기업들은 치료 효과 향상과 유방암 치료의 내성 극복을 위해 AKT(단백질 키나아제 B) 억제제와 선택적 에스트로겐 수용체 분해제(SERD) 병용요법 등 첨단 치료법 개발에 주력하고 있습니다. 이 병용 전략은 암세포의 생존 경로를 억제하는 동시에 에스트로겐 수용체를 분해하여 호르몬 수용체 양성 유방암을 표적으로 삼아 종양의 성장을 억제하고 표준 호르몬 요법에 대한 내성을 해결합니다. 예를 들어, 2023년 11월 영국에 본사를 둔 제약회사 아스트라제네카는 미국 식품의약국(FDA)으로부터 AKT 억제제 트루카프(성분명 : 카피바셀팁)와 선택적 에스트로겐 수용체 분해제 파슬로덱스(성분명 : 플루베스트란트)의 병용요법에 대한 승인을 받았습니다. 이 치료제는 호르몬 수용체(HR) 양성, HER2 음성인 국소 진행성 또는 전이성 유방암 환자 중 PIK3CA, AKT1, PTEN 등 특정 바이오마커 돌연변이가 있고, 최소 한 가지 이상의 내분비 요법에서 진행이 확인되었거나 보조요법 종료 후 12개월 이내에 재발을 경험한 성인 환자 환자를 대상으로 승인되었습니다.

자주 묻는 질문

  • 에스트로겐 차단제 시장 규모는 어떻게 변화하고 있나요?
  • 에스트로겐 차단제 시장의 성장 요인은 무엇인가요?
  • 유방암 유병률 증가는 에스트로겐 차단제 시장에 어떤 영향을 미치나요?
  • 에스트로겐 차단제의 치료 메커니즘은 무엇인가요?
  • 에스트로겐 차단제 시장의 주요 기업들은 어떤 전략을 취하고 있나요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

KSM 26.03.25

Estrogen blockers are substances that reduce the effects of estrogen in the body by either binding to estrogen receptors or lowering estrogen production. They are primarily used to treat estrogen receptor-positive breast cancer by blocking estrogen from promoting cancer cell growth. Additionally, estrogen blockers are employed to manage conditions such as gynecomastia in men, endometriosis, and certain fertility issues by regulating hormone levels.

The main product types of estrogen blockers include selective estrogen receptor modulators (SERMs), aromatase inhibitors, estrogen receptor downregulators (ERDs), and others. Selective estrogen receptor modulators (SERMs) are drugs that interact with estrogen receptors, acting as estrogen agonists in some tissues and antagonists in others. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving applications such as breast cancer treatment, hormone replacement therapy (HRT), infertility treatment, post-menopausal osteoporosis, and more.

Tariffs have impacted the estrogen blockers market by increasing the cost of imported SERMs, aromatase inhibitors, and ERDs, disrupting supply chains and raising treatment costs. Hospital pharmacies, retail pharmacies, and online pharmacies in North America and Europe, which depend on imports, are most affected. Despite these challenges, tariffs have encouraged local production, innovation in combination therapies, and development of cost-efficient estrogen blocker alternatives, potentially enhancing accessibility and diversified availability

The estrogen blockers market research report is one of a series of new reports from The Business Research Company that provides estrogen blockers market statistics, including estrogen blockers industry global market size, regional shares, competitors with a estrogen blockers market share, detailed estrogen blockers market segments, market trends and opportunities, and any further data you may need to thrive in the estrogen blockers industry. This estrogen blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The estrogen blockers market size has grown strongly in recent years. It will grow from $10.05 billion in 2025 to $10.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to limited availability of estrogen blockers, reliance on conventional chemotherapy, increasing incidence of breast cancer, lack of awareness about hormone therapies, growing hospital and oncology clinic infrastructure.

The estrogen blockers market size is expected to see strong growth in the next few years. It will grow to $14.16 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to development of combination therapies and natural estrogen blockers, expansion of personalized medicine approaches, rising adoption of online pharmacy channels, increasing government and healthcare initiatives for breast cancer, growth in advanced diagnostics for hormone receptor testing. Major trends in the forecast period include rising adoption of selective estrogen receptor modulators (serms) and aromatase inhibitors, increasing use of estrogen blockers in hormone replacement therapy (hrt), growth in personalized breast cancer treatment protocols, expansion of online and retail pharmacy distribution channels, rising awareness of infertility and post-menopausal osteoporosis management.

The increasing prevalence of breast cancer is expected to drive the growth of the estrogen blocker market in the coming years. Breast cancer is a malignancy that originates in breast tissue, primarily affecting the milk ducts and lobules. It develops when normal breast cells acquire mutations, leading to uncontrolled cell growth and tumor formation. The rising incidence of breast cancer is attributed to factors such as an aging population, lifestyle changes including higher alcohol consumption and sedentary behavior, and improved detection through enhanced screening and diagnostic methods. Estrogen blockers aid in breast cancer treatment by inhibiting the hormone estrogen, which can stimulate the growth of certain breast cancer cells. By blocking estrogen, these therapies slow or stop the progression of hormone receptor-positive breast cancers, supporting treatment and potentially reducing recurrence. For example, in January 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 20,458 new cases of breast cancer were diagnosed in females in 2023, corresponding to an age-standardized incidence rate of 128.6 cases per 100,000 females. In 2022, an estimated 20,004 cases were reported, with an age-standardized incidence rate of 128.2 per 100,000 females. Therefore, the growing prevalence of breast cancer is contributing to the expansion of the estrogen blocker market.

Leading companies in the estrogen blocker market are focusing on developing advanced therapies, such as combinations of AKT (Protein Kinase B) inhibitors and selective estrogen receptor degraders (SERDs), to improve treatment efficacy and overcome resistance in breast cancer therapy. This combination strategy targets hormone receptor-positive breast cancer by simultaneously inhibiting cancer cell survival pathways and degrading estrogen receptors, thereby limiting tumor growth and addressing resistance to standard hormonal treatments. For instance, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Truqap (capivasertib), an AKT inhibitor, in combination with Faslodex (fulvestrant), a selective estrogen receptor degrader. This therapy is approved for adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer who have specific biomarker alterations, including PIK3CA, AKT1, or PTEN, and who have either progressed on at least one endocrine therapy or experienced recurrence within 12 months after completing adjuvant therapy.

In July 2024, Exscientia, a UK-based biotechnology company, acquired GT Apeiron's stake in its oral CDK7 inhibitor program for an undisclosed amount. This acquisition strengthens Exscientia's oncology portfolio and supports plans to develop combination therapies for HR+/HER2- breast cancer by late 2024. The development aligns with the company's focus on AI-driven drug design to create highly effective cancer treatments. GT Apeiron is a US-based company specializing in applied artificial intelligence (AI) and drug discovery.

Major companies operating in the estrogen blockers market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc, Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alvogen Inc., Alembic Pharmaceuticals Limited, Olema Pharmaceuticals Inc, Cipla Inc, Criterium Inc

North America was the largest region in the estrogen blockers market in 2025. The regions covered in the estrogen blockers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the estrogen blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The estrogen blockers market consists of sales of tamoxifen, raloxifene, toremifene, anastrozole, letrozole, exemestane, and fulvestrant. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Estrogen Blockers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses estrogen blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for estrogen blockers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The estrogen blockers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Downregulators (ERDs); Other Products
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By Application: Breast Cancer Treatment; Hormone Replacement Therapy (HRT); Infertility Treatment; Post-Menopausal Osteoporosis; Other Applications
  • Subsegments:
  • 1) By Selective Estrogen Receptor Modulators (SERMs): Tamoxifen; Raloxifene; Toremifene; Fulvestrant
  • 2) By Aromatase Inhibitors: Anastrozole; Letrozole; Exemestane; Vorozole
  • 3) By Estrogen Receptor Downregulators (ERDs): Fulvestrant; Elacestrant; Giredestrant
  • 4) By Other Products: Phytochemicals; Natural Estrogen Blockers; Combination Therapies
  • Companies Mentioned: Pfizer Inc; F. Hoffmann-La Roche AG; Merck & Co. Inc; Novartis AG; Sanofi S.A; AstraZeneca PLC; GlaxoSmithKline plc; Eli Lilly and Company; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Sun Pharmaceutical Industries Ltd.; Ipsen S.A.; Cadila Pharmaceuticals Ltd.; Intas Pharmaceuticals Limited; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Amneal Pharmaceuticals Inc.; Lupin Limited; Glenmark Pharmaceuticals Limited; Alvogen Inc.; Alembic Pharmaceuticals Limited; Olema Pharmaceuticals Inc; Cipla Inc; Criterium Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Estrogen Blockers Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Estrogen Blockers Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Estrogen Blockers Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Estrogen Blockers Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Selective Estrogen Receptor Modulators (Serms) And Aromatase Inhibitors
    • 4.2.2 Increasing Use Of Estrogen Blockers In Hormone Replacement Therapy (Hrt)
    • 4.2.3 Growth In Personalized Breast Cancer Treatment Protocols
    • 4.2.4 Expansion Of Online And Retail Pharmacy Distribution Channels
    • 4.2.5 Rising Awareness Of Infertility And Post-Menopausal Osteoporosis Management

5. Estrogen Blockers Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Oncology Clinics
  • 5.3 Retail Pharmacies
  • 5.4 Online Pharmacies
  • 5.5 Hormone Therapy Centers

6. Estrogen Blockers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Estrogen Blockers Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Estrogen Blockers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Estrogen Blockers Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Estrogen Blockers Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Estrogen Blockers Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Estrogen Blockers Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Estrogen Blockers Market Segmentation

  • 9.1. Global Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs), Other Products
  • 9.2. Global Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • 9.3. Global Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Breast Cancer Treatment, Hormone Replacement Therapy (HRT), Infertility Treatment, Post-Menopausal Osteoporosis, Other Applications
  • 9.4. Global Estrogen Blockers Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Tamoxifen, Raloxifene, Toremifene, Fulvestrant
  • 9.5. Global Estrogen Blockers Market, Sub-Segmentation Of Aromatase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Anastrozole, Letrozole, Exemestane, Vorozole
  • 9.6. Global Estrogen Blockers Market, Sub-Segmentation Of Estrogen Receptor Downregulators (ERDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fulvestrant, Elacestrant, Giredestrant
  • 9.7. Global Estrogen Blockers Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Phytochemicals, Natural Estrogen Blockers, Combination Therapies

10. Estrogen Blockers Market Regional And Country Analysis

  • 10.1. Global Estrogen Blockers Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Estrogen Blockers Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Estrogen Blockers Market

  • 11.1. Asia-Pacific Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Estrogen Blockers Market

  • 12.1. China Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Estrogen Blockers Market

  • 13.1. India Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Estrogen Blockers Market

  • 14.1. Japan Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Estrogen Blockers Market

  • 15.1. Australia Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Estrogen Blockers Market

  • 16.1. Indonesia Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Estrogen Blockers Market

  • 17.1. South Korea Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Estrogen Blockers Market

  • 18.1. Taiwan Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Estrogen Blockers Market

  • 19.1. South East Asia Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Estrogen Blockers Market

  • 20.1. Western Europe Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Estrogen Blockers Market

  • 21.1. UK Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Estrogen Blockers Market

  • 22.1. Germany Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Estrogen Blockers Market

  • 23.1. France Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Estrogen Blockers Market

  • 24.1. Italy Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Estrogen Blockers Market

  • 25.1. Spain Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Estrogen Blockers Market

  • 26.1. Eastern Europe Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Estrogen Blockers Market

  • 27.1. Russia Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Estrogen Blockers Market

  • 28.1. North America Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Estrogen Blockers Market

  • 29.1. USA Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Estrogen Blockers Market

  • 30.1. Canada Estrogen Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Estrogen Blockers Market

  • 31.1. South America Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Estrogen Blockers Market

  • 32.1. Brazil Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Estrogen Blockers Market

  • 33.1. Middle East Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Estrogen Blockers Market

  • 34.1. Africa Estrogen Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Estrogen Blockers Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Estrogen Blockers Market Regulatory and Investment Landscape

36. Estrogen Blockers Market Competitive Landscape And Company Profiles

  • 36.1. Estrogen Blockers Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Estrogen Blockers Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Estrogen Blockers Market Company Profiles
    • 36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

37. Estrogen Blockers Market Other Major And Innovative Companies

  • AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals Limited

38. Global Estrogen Blockers Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Estrogen Blockers Market

40. Estrogen Blockers Market High Potential Countries, Segments and Strategies

  • 40.1 Estrogen Blockers Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Estrogen Blockers Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Estrogen Blockers Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제